Market Intelligence, Clinical Progress, and High-Purity Reagents for Solid Tumor Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GPC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPC1 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin controlled (<1 EU/µg). HEK293 expressed for native glycosylation. Sequence Verified. |
View GPC1 Products |
| Gene Delivery | GPC1 Promise-ORF / Lentivirus Full-length GPC1 ORF for stable cell line construction and flow cytometry validation. |
View GPC1 Products |
| Benchmark Ab | Anti-GPC1 Recombinant Antibody (Miltuximab Biosimilar) Recombinant positive control for binding and internalization assays. |
View GPC1 Products |
| Validator | GPC1 siRNA Set Target-specific knockdown verification in target-positive cancer cell lines. |
View GPC1 Products |
| Related Target A | GPC3 (Glypican 3) Highly homologous glypican family member; crucial for off-target selectivity screening in liver and lung cancers. |
View GPC3 Products |
| Related Target B | MSLN (Mesothelin) Co-expressed with GPC1 in pancreatic ductal adenocarcinoma (PDAC); key target for combination or bispecific therapies. |
View MSLN Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding Interference (Soluble GPC1 Decoy) | HEK293-expressed GPC1 ECD-Fc with precise C-terminal truncation to mimic physiological soluble GPC1 for decoy-binding assays. |
| Glypican Subfamily Off-Target Cross-Reactivity | Homologous GPC3 and GPC5 recombinant protein panels strictly verified by mass spectrometry for selectivity profiling. |
| Lack of Validated Positive Controls | Recombinant sequence-matched Miltuximab biosimilar included for benchmark binding and internalization assays. |
| False Positive Screening in Cell Lines | Sequence-verified GPC1 siRNA pool for target-specific knockdown to confirm antibody specificity. |
Live GPC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GPC1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to antibody-drug conjugates (ADCs), radioligand therapies (RLTs), and CAR-T cell therapies. As first-generation therapies like Miltuximab establish clinical safety, the next wave of R&D is targeting GPC1 in highly refractory solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC), glioblastoma multiforme (GBM), and esophageal squamous cell carcinoma (ESCC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Antibody-Drug Conjugate (ADC) | AstraZeneca, Heidelberg Pharma | Pancreatic Cancer, Solid Tumors | Internalization Assay (Need high-purity GPC1 ECD-Fc to validate antibody-antigen complex endocytosis) |
| Radioligand Therapy (RLT) | Minomic International | Prostate Cancer, Bladder Cancer | Affinity & Retention Validation (Need high-purity monomeric GPC1 for precise SPR kinetics) |
| CAR-T / Cell Therapy | Academic Institutions, Biotech Startups | Glioblastoma, Solid Tumors | Target Density & Specificity (Need GPC1 Lentivirus for stable cell line generation to evaluate CAR-T cytolytic activity) |